126 related articles for article (PubMed ID: 28103256)
41. Multiparametric magnetic resonance imaging features of a canine glioblastoma model.
Lee S; Choi SH; Cho HR; Koh J; Park CK; Ichikawa T
PLoS One; 2021; 16(7):e0254448. PubMed ID: 34242365
[TBL] [Abstract][Full Text] [Related]
42. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
Moon HH; Kim HS; Park JE; Kim YH; Kim JH
BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
[TBL] [Abstract][Full Text] [Related]
43. Quantitative mapping of individual voxels in the peritumoral region of IDH-wildtype glioblastoma to distinguish between tumor infiltration and edema.
Dasgupta A; Geraghty B; Maralani PJ; Malik N; Sandhu M; Detsky J; Tseng CL; Soliman H; Myrehaug S; Husain Z; Perry J; Lau A; Sahgal A; Czarnota GJ
J Neurooncol; 2021 Jun; 153(2):251-261. PubMed ID: 33905055
[TBL] [Abstract][Full Text] [Related]
44. Visualizing Glioma Infiltration by the Combination of Multimodality Imaging and Artificial Intelligence, a Systematic Review of the Literature.
d'Este SH; Nielsen MB; Hansen AE
Diagnostics (Basel); 2021 Mar; 11(4):. PubMed ID: 33806195
[TBL] [Abstract][Full Text] [Related]
45. Diffusion histology imaging differentiates distinct pediatric brain tumor histology.
Ye Z; Srinivasa K; Meyer A; Sun P; Lin J; Viox JD; Song C; Wu AT; Song SK; Dahiya S; Rubin JB
Sci Rep; 2021 Feb; 11(1):4749. PubMed ID: 33637807
[TBL] [Abstract][Full Text] [Related]
46. Intraoperative Mass Spectrometry Platform for IDH Mutation Status Prediction, Glioma Diagnosis, and Estimation of Tumor Cell Infiltration.
Brown HM; Alfaro CM; Pirro V; Dey M; Hattab EM; Cohen-Gadol AA; Cooks RG
J Appl Lab Med; 2021 Jul; 6(4):902-916. PubMed ID: 33523209
[TBL] [Abstract][Full Text] [Related]
47. A Nomogram Predicts Individual Prognosis in Patients With Newly Diagnosed Glioblastoma by Integrating the Extent of Resection of Non-Enhancing Tumors.
Zhang Z; Jin Z; Liu D; Zhang Y; Li C; Miao Y; Chi X; Feng J; Wang Y; Hao S; Ji N
Front Oncol; 2020; 10():598965. PubMed ID: 33344248
[TBL] [Abstract][Full Text] [Related]
48. Distributed changes of the functional connectome in patients with glioblastoma.
Nenning KH; Furtner J; Kiesel B; Schwartz E; Roetzer T; Fortelny N; Bock C; Grisold A; Marko M; Leutmezer F; Liu H; Golland P; Stoecklein S; Hainfellner JA; Kasprian G; Prayer D; Marosi C; Widhalm G; Woehrer A; Langs G
Sci Rep; 2020 Oct; 10(1):18312. PubMed ID: 33110138
[TBL] [Abstract][Full Text] [Related]
49. Quantitative MRI using relaxometry in malignant gliomas detects contrast enhancement in peritumoral oedema.
Blystad I; Warntjes JBM; Smedby Ö; Lundberg P; Larsson EM; Tisell A
Sci Rep; 2020 Oct; 10(1):17986. PubMed ID: 33093605
[TBL] [Abstract][Full Text] [Related]
50. Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients.
Regnery S; Behl NGR; Platt T; Weinfurtner N; Windisch P; Deike-Hofmann K; Sahm F; Bendszus M; Debus J; Ladd ME; Schlemmer HP; Rieken S; Adeberg S; Paech D
Neuroimage Clin; 2020; 28():102427. PubMed ID: 33002860
[TBL] [Abstract][Full Text] [Related]
51. Assessment of Pre-operative Measurements of Tumor Size by MRI Methods as Survival Predictors in Wild Type IDH Glioblastoma.
Palpan Flores A; Vivancos Sanchez C; Roda JM; Cerdán S; Barrios AJ; Utrilla C; Royo A; Gandía González ML
Front Oncol; 2020; 10():1662. PubMed ID: 32984040
[No Abstract] [Full Text] [Related]
52. Development of a Rat Model for Glioma-Related Epilepsy.
Bouckaert C; Germonpré C; Verhoeven J; Chong SA; Jacquin L; Mairet-Coello G; André VM; Leclercq K; Vanhove C; De Vos F; Van den Broecke C; Goethals I; Descamps B; Donche S; Carrette E; Wadman W; Boon P; Vonck K; Raedt R
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977526
[TBL] [Abstract][Full Text] [Related]
53. Functional connectivity within glioblastoma impacts overall survival.
Daniel AGS; Park KY; Roland JL; Dierker D; Gross J; Humphries JB; Hacker CD; Snyder AZ; Shimony JS; Leuthardt EC
Neuro Oncol; 2021 Mar; 23(3):412-421. PubMed ID: 32789494
[TBL] [Abstract][Full Text] [Related]
54. The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma.
Incekara F; Smits M; van der Voort SR; Dubbink HJ; Atmodimedjo PN; Kros JM; Vincent AJPE; van den Bent M
Front Oncol; 2020; 10():1087. PubMed ID: 32766140
[No Abstract] [Full Text] [Related]
55. Temporospatial genomic profiling in glioblastoma identifies commonly altered core pathways underlying tumor progression.
Blomquist MR; Ensign SF; D'Angelo F; Phillips JJ; Ceccarelli M; Peng S; Halperin RF; Caruso FP; Garofano L; Byron SA; Liang WS; Craig DW; Carpten JD; Prados MD; Trent JM; Berens ME; Iavarone A; Dhruv H; Tran NL
Neurooncol Adv; 2020; 2(1):vdaa078. PubMed ID: 32743548
[TBL] [Abstract][Full Text] [Related]
56. Deep learning for glioblastoma segmentation using preoperative magnetic resonance imaging identifies volumetric features associated with survival.
Wan Y; Rahmat R; Price SJ
Acta Neurochir (Wien); 2020 Dec; 162(12):3067-3080. PubMed ID: 32662042
[TBL] [Abstract][Full Text] [Related]
57. Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes.
Bovi JA; Prah MA; Retzlaff AA; Schmainda KM; Connelly JM; Rand SD; Marszalkowski CS; Mueller WM; Siker ML; Schultz CJ
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):979-986. PubMed ID: 32599030
[TBL] [Abstract][Full Text] [Related]
58. Blood-Brain Barrier, Blood-Brain Tumor Barrier, and Fluorescence-Guided Neurosurgical Oncology: Delivering Optical Labels to Brain Tumors.
Belykh E; Shaffer KV; Lin C; Byvaltsev VA; Preul MC; Chen L
Front Oncol; 2020; 10():739. PubMed ID: 32582530
[TBL] [Abstract][Full Text] [Related]
59. A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma.
Jackson C; Choi J; Khalafallah AM; Price C; Bettegowda C; Lim M; Gallia G; Weingart J; Brem H; Mukherjee D
J Neurooncol; 2020 Jul; 148(3):419-431. PubMed ID: 32562247
[TBL] [Abstract][Full Text] [Related]
60. Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery.
Grossman SA; Romo CG; Rudek MA; Supko J; Fisher J; Nabors LB; Wen PY; Peereboom DM; Ellingson BM; Elmquist W; Barker FG; Kamson D; Sarkaria JN; Timmer W; Bindra RS; Ye X
Neuro Oncol; 2020 Oct; 22(10):1422-1424. PubMed ID: 32506123
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
